| 前收市價 | 113.10 |
| 開市 | 113.63 |
| 買盤 | 110.07 x 800 |
| 賣出價 | 115.00 x 900 |
| 今日波幅 | 113.01 - 114.34 |
| 52 週波幅 | 89.67 - 121.64 |
| 成交量 | |
| 平均成交量 | 6,195,906 |
| 市值 | 198.105B |
| Beta 值 (5 年，每月) | 0.72 |
| 市盈率 (最近 12 個月) | 35.92 |
| 每股盈利 (最近 12 個月) | 3.17 |
| 業績公佈日 | 2024年10月16日 - 2024年10月21日 |
| 遠期股息及收益率 | 2.20 (1.93%) |
| 除息日 | 2024年7月15日 |
| 1 年預測目標價 | 124.04 |
ZacksAbbott's Lingo CGM System Gains U.S. Availability: Stock to Gain?
ABT made its CGM system Lingo available in the United States. The system can be used by consumers aged 18 years and older who are not on insulin.
Investor's Business DailyHow Abbott Labs Is Leaning Into Obesity Treatment, And Taking On Dexcom
Abbott Laboratories launched its newest CGM in the U.S. on Thursday. The biosensor named Lingo is the first-ever for people without diabetes.
BenzingaAbbott Laboratories Recalls Some Sensors For Its Popular FreeStyle Libre 3 Glucose Monitoring System
Thursday, Abbott Laboratories (NYSE:ABT) said it is recalling some FreeStyle Libre 3 sensors after finding that a small number of FreeStyle Libre 3 sensors may provide incorrect high glucose readings. The use of the affected product may cause serious adverse health consequences, including severe low blood sugar (hypoglycemia), which can cause central nervous system problems, loss of consciousness, seizures, coma, permanent brain damage, and death. There have been two reported injuries. There hav
